Susana Núñez-Pereira

Susana Núñez-Pereira


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 March 2023 in Antibiotics
Verified
Journal Article
Open access
PDF file
SNSusana Núñez-Pereira
Susana Núñez-Pereira
EBEva Benavent
Eva Benavent
MUMarat Ulldemolins
Marat Ulldemolins
BSBeatriz Sobrino-Díaz
Beatriz Sobrino-Díaz
JIJosé Antonio Iribarren
José Antonio Iribarren
OMon behalf of GEIO–SEIMC (Group for the Study of Osteoarticular Infections–Spanish Society of Infectious Diseases and Clinical Microbiology)
on behalf of GEIO–SEIMC (Group for the Study of Osteoarticular Infections–Spanish Society of Infectious Diseases and Clinical Microbiology)
Infection after spinal instrumentation (IASI) by Cutibacterium spp. is being more frequently reported. The aim of this study was to analyse the incidence, risk factors, clinical characteristics, and outcome of a Cutibacterium spp. IASI (CG) compared with non-Cutibacterium IASI (NCG) infections, with an additional focus on the role of rifampin in the treatment. All patients from a multicentre, retrospective, observational study with a confirmed IASI between January 2010 and December 2016 were divided into two groups: (CG and NCG) IASI. Baseline, medical, surgical, infection treatment, and follow-up data were compared for both groups. In total, 411 patients were included: 27 CG and 384 NCG. The CG patients were significantly younger. They had a longer median time to diagnosis (23 vs. 13 days) (p = 0.025), although 55.6% debuted within the first month after surgery. Cutibacterium patients were more likely to have the implant removed (29.6% vs. 12.8%; p = 0.014) and received shorter antibiotic regimens (p = 0.014). In 33% of Cutibacterium cases, rifampin was added to the baseline therapy. None of the 27 infections resulted in treatment failure during follow-up regardless of rifampin use. Cutibacterium spp. is associated with a younger age and may cause both early and late IASIs. In our experience, the use of rifampin to improve the outcome in the treatment of a Cutibacterium spp. IASI is not relevant since, in our series, none of the cases had therapeutic failure regardless of the use of rifampin.